Access the full text.
Sign up today, get DeepDyve free for 14 days.
(2014)
Research Original Investigation Nabiximols in Cannabis Withdrawal 290 JAMA Psychiatry Number 3 jamapsychiatry.com Copyright
Paul Zhang (2003)
Multiple Imputation: Theory and MethodInternational Statistical Review, 71
W. Swift, J. Copeland, Wayne Hall (1998)
Choosing a diagnostic cut-off for cannabis dependence.Addiction, 93 11
D. Gorelick, Kenneth Levin, M. Copersino, S. Heishman, Fang Liu, D. Boggs, D. Kelly (2012)
Diagnostic criteria for cannabis withdrawal syndrome.Drug and alcohol dependence, 123 1-3
C. Mallinckrodt, W. Clark, Ray Carroll, G. Molenberghs (2003)
Assessing Response Profiles from Incomplete Longitudinal Clinical Trial Data Under Regulatory ConsiderationsJournal of Biopharmaceutical Statistics, 13
(2013)
Report 2011
G. Vaillant (1988)
What can long-term follow-up teach us about relapse and prevention of relapse in addiction?British journal of addiction, 83 10
M. Copersino, S. Boyd, D. Tashkin, M. Huestis, S. Heishman, J. Dermand, M. Simmons, D. Gorelick (2006)
Cannabis withdrawal among non-treatment-seeking adult cannabis users.The American journal on addictions, 15 1
R. Stephens, J. Wertz, R. Roffman (1995)
Self-efficacy and marijuana cessation: a construct validity analysis.Journal of consulting and clinical psychology, 63 6
R. Vandrey, M. Haney (2009)
Pharmacotherapy for Cannabis DependenceCNS Drugs, 23
L. Magee (1990)
R 2 Measures Based on Wald and Likelihood Ratio Joint Significance TestsThe American Statistician, 44
Peter Lawrinson, J. Copeland, Devon Indig (2005)
Development and validation of a brief instrument for routine outcome monitoring in opioid maintenance pharmacotherapy services: the brief treatment outcome measure (BTOM).Drug and alcohol dependence, 80 1
J. Crippa, J. Hallak, J. MACHADO-DE-SOUSA, Regina Queiroz, M. Bergamaschi, Marcos Chagas, A. Zuardi (2013)
Cannabidiol for the treatment of cannabis withdrawal syndrome: a case reportJournal of Clinical Pharmacy and Therapeutics, 38
M. Bell, D. Fairclough (2014)
Practical and statistical issues in missing data for longitudinal patient-reported outcomesStatistical Methods in Medical Research, 23
P. Robson (2011)
Abuse potential and psychoactive effects of δ-9-tetrahydrocannabinol and cannabidiol oromucosal spray (Sativex), a new cannabinoid medicineExpert Opinion on Drug Safety, 10
L. Hedges (1981)
Distribution Theory for Glass's Estimator of Effect size and Related EstimatorsJournal of Educational Statistics, 6
M. Haney (2005)
The marijuana withdrawal syndrome: Diagnosis and treatmentCurrent Psychiatry Reports, 7
J. Patton, M. Stanford, E. Barratt (1995)
Factor structure of the Barratt impulsiveness scale.Journal of clinical psychology, 51 6
(2011)
Quitting Cannabis in 8 Days: Self-guided Manual. Sydney, Australia: National Cannabis Prevention and Information Centre
(1982)
Psychopharmacology (Berl)
F. Levin, D. Mcdowell, S. Evans, E. Nunes, E. Akerele, S. Donovan, S. Vosburg (2004)
Pharmacotherapy for marijuana dependence: a double-blind, placebo-controlled pilot study of divalproex sodium.The American journal on addictions, 13 1
A. Zuardi, R. Cosme, Frederico Graeff, Francisco Guimarães (1993)
Effects of ipsapirone and cannabidiol on human experimental anxietyJournal of Psychopharmacology, 7
(2012)
Transl Psychiatry
F. Leweke, D. Piomelli, D. Piomelli, F. Pahlisch, F. Pahlisch, D. Muhl, D. Muhl, C. Gerth, C. Hoyer, C. Hoyer, J. Klosterkötter, M. Hellmich, D. Koethe, D. Koethe (2012)
Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophreniaTranslational Psychiatry, 2
Melissa Norberg, J. Mackenzie, J. Copeland (2012)
Quantifying cannabis use with the timeline followback approach: a psychometric evaluation.Drug and alcohol dependence, 121 3
F. Levin, J. Mariani, D. Brooks, M. Pavlicova, Wendy Cheng, E. Nunes (2011)
Dronabinol for the treatment of cannabis dependence: a randomized, double-blind, placebo-controlled trial.Drug and alcohol dependence, 116 1-3
M. Haney, Z. Cooper, G. Bedi, S. Vosburg, S. Comer, R. Foltin (2013)
Nabilone Decreases Marijuana Withdrawal and a Laboratory Measure of Marijuana RelapseNeuropsychopharmacology, 38
J. Simons, Raluca Gaher (2005)
The Distress Tolerance Scale: Development and Validation of a Self-Report MeasureMotivation and Emotion, 29
J. Copeland, S. Gilmour, P. Gates, W. Swift (2005)
The Cannabis Problems Questionnaire: factor structure, reliability, and validity.Drug and alcohol dependence, 80 3
Randolph Arnau, J. Broman-Fulks, B. Green, M. Berman (2009)
The Anxiety Sensitivity Index—RevisedAssessment, 16
M. Haney, A. Ward, S. Comer, C. Hart, R. Foltin, M. Fischman (2001)
Bupropion SR worsens mood during marijuana withdrawal in humansPsychopharmacology, 155
J. Schafer (1999)
Multiple imputation: a primerStatistical Methods in Medical Research, 8
D. Wade, P. Makela, P. Robson, Heather House, C. Bateman (2004)
Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patientsMultiple Sclerosis, 10
A. Zuardi, I. Shirakawa, E. Finkelfarb, I. Karniol (2004)
Action of cannabidiol on the anxiety and other effects produced by δ9-THC in normal subjectsPsychopharmacology, 76
D. Allsop, Melissa Norberg, J. Copeland, S. Fu, A. Budney (2011)
The Cannabis Withdrawal Scale development: patterns and predictors of cannabis withdrawal and distress.Drug and alcohol dependence, 119 1-2
D. Rog, T. Nurmikko, C. Young (2007)
Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial.Clinical therapeutics, 29 9
Jordi Perez (2006)
Combined cannabinoid therapy via an oromucosal spray.Drugs of today, 42 8
Erin Karschner, W. Darwin, R. Goodwin, S. Wright, M. Huestis (2011)
Plasma cannabinoid pharmacokinetics following controlled oral delta9-tetrahydrocannabinol and oromucosal cannabis extract administration.Clinical chemistry, 57 1
U. Preuss, A. Watzke, J. Zimmermann, J. Wong, C. Schmidt (2010)
Cannabis withdrawal severity and short-term course among cannabis-dependent adolescent and young adult inpatients.Drug and alcohol dependence, 106 2-3
D. Hasin, K. Keyes, D. Alderson, Shuang Wang, E. Aharonovich, B. Grant (2008)
Cannabis withdrawal in the United States: results from NESARC.The Journal of clinical psychiatry, 69 9
T. Chung, C. Martin, J. Cornelius, D. Clark (2008)
Cannabis withdrawal predicts severity of cannabis involvement at 1-year follow-up among treated adolescents.Addiction, 103 5
I. Karniol, I. Shirakawa, N. Kasinski, A. Pfeferman, E. Carlini (1974)
Cannabidiol interferes with the effects of delta 9 - tetrahydrocannabinol in man.European journal of pharmacology, 28 1
C. Soldatos, D. Dikeos, T. Paparrigopoulos (2000)
Athens Insomnia Scale: validation of an instrument based on ICD-10 criteria.Journal of psychosomatic research, 48 6
A. Budney, R. Vandrey, J. Hughes, B. Moore, Betsy Bahrenburg (2007)
Oral delta-9-tetrahydrocannabinol suppresses cannabis withdrawal symptoms.Drug and alcohol dependence, 86 1
D. Allsop, J. Copeland, Melissa Norberg, S. Fu, A. Molnár, John Lewis, A. Budney (2012)
Quantifying the Clinical Significance of Cannabis WithdrawalPLoS ONE, 7
Karin Verweij, A. Agrawal, N. Nat, H. Creemers, Anja Huizink, N. Martin, M. Lynskey (2012)
A genetic perspective on the proposed inclusion of cannabis withdrawal in DSM-5Psychological Medicine, 43
A. Leon, M. Olfson, L. Portera, L. Farber, D. Sheehan (1997)
Assessing Psychiatric Impairment in Primary Care with the Sheehan Disability ScaleThe International Journal of Psychiatry in Medicine, 27
Aviv Weinstein, D. Gorelick (2011)
Pharmacological treatment of cannabis dependence.Current pharmaceutical design, 17 14
B. Deacon, J. Abramowitz, Carol Woods, D. Tolin (2003)
The Anxiety Sensitivity Index - Revised: psychometric properties and factor structure in two nonclinical samples.Behaviour research and therapy, 41 12
A. Schier, Natalia Ribeiro, A. Silva, J. Hallak, J. Crippa, A. Nardi, A. Zuardi (2012)
Cannabidiol, a Cannabis sativa constituent, as an anxiolytic drug.Revista brasileira de psiquiatria, 34 Suppl 1
M. Haney, C. Hart, S. Vosburg, Jennifer Nasser, Andrew Bennett, C. Zubaran, R. Foltin (2004)
Marijuana Withdrawal in Humans: Effects of Oral THC or DivalproexNeuropsychopharmacology, 29
Amir Englund, P. Morrison, J. Nottage, D. Hague, F. Kane, S. Bonaccorso, J. Stone, A. Reichenberg, R. Brenneisen, D. Holt, A. Feilding, Lucy Walker, R. Murray, S. Kapur (2013)
Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairmentJournal of Psychopharmacology, 27
A. Benyamina, Marie Lecacheux, L. Blecha, M. Reynaud, Michael Lukasiewcz (2008)
Pharmacotherapy and psychotherapy in cannabis withdrawal and dependenceExpert Review of Neurotherapeutics, 8
D. Rubin (1975)
INFERENCE AND MISSING DATAPsychometrika, 1975
G. Norman (2010)
Likert scales, levels of measurement and the “laws” of statisticsAdvances in Health Sciences Education, 15
G. Martin, J. Copeland, P. Gates, S. Gilmour (2006)
The Severity of Dependence Scale (SDS) in an adolescent population of cannabis users: reliability, validity and diagnostic cut-off.Drug and alcohol dependence, 83 1
(2007)
Clin Ther
M. First, R. Spitzer, F. Gibon, Jbw Williams (2002)
Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research version (SCID-I RV)
(2014)
Downloaded From: http://archpsyc.jamanetwork.com/pdfaccess.ashx?url=/data/journals/psych/929807/ on 04
H. Akaike (1974)
A new look at the statistical model identificationIEEE Transactions on Automatic Control, 19
M. Haney, G. Bedi, Z. Cooper, Andrew Glass, S. Vosburg, S. Comer, R. Foltin (2013)
Predictors of Marijuana Relapse in the Human Laboratory: Robust Impact of Tobacco Cigarette Smoking StatusBiological Psychiatry, 73
K. Schoedel, N. Chen, A. Hilliard, L. White, C. Stott, Ethan Russo, S. Wright, G. Guy, M. Romach, E. Sellers (2011)
A randomized, double‐blind, placebo‐controlled, crossover study to evaluate the subjective abuse potential and cognitive effects of nabiximols oromucosal spray in subjects with a history of recreational cannabis useHuman Psychopharmacology: Clinical and Experimental, 26
K. Carpenter, D. Mcdowell, D. Brooks, Wendy Cheng, F. Levin (2009)
A preliminary trial: double-blind comparison of nefazodone, bupropion-SR, and placebo in the treatment of cannabis dependence.The American journal on addictions, 18 1
R. Roffman, R. Stephens, G. Marlatt (2010)
Cannabis Dependence: Its Nature, Consequences and Treatment
W. Swift, Alexander Wong, Kong Li, J. Arnold, I. McGregor (2013)
Analysis of Cannabis Seizures in NSW, Australia: Cannabis Potency and Cannabinoid ProfilePLoS ONE, 8
W. Hall, L. Degenhardt (2009)
Adverse health effects of non-medical cannabis useThe Lancet, 374
A. Budney, J. Hughes (2006)
The cannabis withdrawal syndromeCurrent Opinion in Psychiatry, 19
A. Campos, F. Moreira, F. Gomes, E. Bel, F. Guimarães (2012)
Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disordersPhilosophical Transactions of the Royal Society B: Biological Sciences, 367
J. Cornelius, T. Chung, C. Martin, D. Wood, D. Clark (2008)
Cannabis withdrawal is common among treatment-seeking adolescents with cannabis dependence and major depression, and is associated with rapid relapse to dependence.Addictive behaviors, 33 11
A. Winstock, Toby Lea, Jan Copeland (2009)
Lithium carbonate in the management of cannabis withdrawal in humans: an open-label studyJournal of Psychopharmacology, 23
F. Levin, J. Mariani, D. Brooks, S. Xie, K. Murray (2010)
Delta9-tetrahydrocannabivarin testing may not have the sensitivity to detect marijuana use among individuals ingesting dronabinol.Drug and alcohol dependence, 106 1
S. Lovibond, P. Lovibond (2011)
Depression Anxiety Stress Scales
M. Haney, C. Hart, S. Vosburg, S. Comer, S. Reed, R. Foltin (2008)
Effects of THC and lofexidine in a human laboratory model of marijuana withdrawal and relapsePsychopharmacology, 197
E. Russo, G. Guy, P. Robson (2007)
Cannabis, Pain, and Sleep: Lessons from Therapeutic Clinical Trials of Sativex®, a Cannabis‐Based MedicineChemistry & Biodiversity, 4
J. Sastre-Garriga, C. Vila, S. Clissold, X. Montalban (2011)
THC and CBD oromucosal spray (Sativex®) in the management of spasticity associated with multiple sclerosisExpert Review of Neurotherapeutics, 11
R. Vandrey, M. Stitzer, M. Mintzer, M. Huestis, Jeannie Murray, Dayong Lee (2013)
The dose effects of short-term dronabinol (oral THC) maintenance in daily cannabis users.Drug and alcohol dependence, 128 1-2
ImportanceThere are no medications approved for treating cannabis dependence or withdrawal. The cannabis extract nabiximols (Sativex), developed as a multiple sclerosis treatment, offers a potential agonist medication for cannabis withdrawal. ObjectiveTo evaluate the safety and efficacy of nabiximols in treating cannabis withdrawal. Design, Setting, and ParticipantsA 2-site, double-blind randomized clinical inpatient trial with a 28-day follow-up was conducted in New South Wales, Australia. Participants included 51 DSM-IV-TR cannabis-dependent treatment seekers. InterventionsA 6-day regimen of nabiximols (maximum daily dose, 86.4 mg of Δ9-tetrahydrocannabinol and 80 mg of cannabidiol) or placebo with standardized psychosocial interventions during a 9-day admission. Main Outcomes and MeasuresSeverity of cannabis withdrawal and cravings (Cannabis Withdrawal Scale), retention in withdrawal treatment, and adverse events. Secondary outcomes include postwithdrawal cannabis use, health outcomes, and psychosocial outcomes. ResultsNabiximols treatment significantly reduced the overall severity of cannabis withdrawal relative to placebo (F8,377.97 = 2.39; P = .01), including effects on withdrawal-related irritability, depression, and cannabis cravings. Nabiximols had a more limited, but still positive, therapeutic benefit on sleep disturbance, anxiety, appetite loss, physical symptoms, and restlessness. Nabiximols patients remained in treatment longer during medication use (unadjusted hazard ratio, 3.66 [95% CI, 1.18-11.37]; P = .02), with 2.84 the number needed to treat to achieve successful retention in treatment. Participants could not reliably differentiate between nabiximols and placebo treatment (χ21 = 0.79; P = .67), and those receiving nabiximols did not report greater intoxication (F1,6 = 0.22; P = .97). The number (F1,50 = 0.3; P = .59) and severity (F1,50 = 2.69; P = .10) of adverse events did not differ significantly between groups. Both groups showed reduced cannabis use at follow-up, with no advantage of nabiximols over placebo for self-reported cannabis use (F1,48 = 0.29; P = .75), cannabis-related problems (F1,49 = 2.33; P = .14), or cannabis dependence (F1,50 < 0.01; P = .89). Conclusions and RelevanceIn a treatment-seeking cohort, nabiximols attenuated cannabis withdrawal symptoms and improved patient retention in treatment. However, placebo was as effective as nabiximols in promoting long-term reductions in cannabis use following medication cessation. The data support further evaluation of nabiximols for management of cannabis dependence and withdrawal in treatment-seeking populations. Trial Registrationanzctr.org.au Identifier: ACTRN12611000398909
JAMA Psychiatry – American Medical Association
Published: Mar 1, 2014
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.